OncLive Poised to Induct 2019 Class of ‘Giants of Cancer Care’
OncLive, a digital resource platform for oncologists, will welcome 15 new members at its 7th Annual Giants of Cancer Care Winners Reception on May 30 in…
News
Allogene’s CAR T-cell Therapy Triggers Durable Anti-Tumor Response in Animal Model
ALLO-715, Allogene Therapeutics‘ donor-derived CAR T-cell therapy, can trigger a durable anti-tumor response in mice with multiple myeloma, and maintain its characteristics and…
Kyprolis Combo Shows Promise for Newly Diagnosed, Transplant-eligible Patients
A triple regimen composed of Kyprolis (carfilzomib), thalidomide, and dexamethasone, given before and after high-dose chemotherapy and autologous stem cell transplant, is safe…
bluebird bio Opens Manufacturing, Research Facility in Durham, N.C.
Bluebird bio has officially opened a facility in Durham, North Carolina, to make the lentiviral vector needed for its investigational gene and cell treatments, including…
Ninlaro Maintenance Therapy Prolongs and Boosts Treatment Benefits in Myeloma Patients, Study Says
Maintenance therapy with Ninlaro (ixazomib) can prolong and boost therapeutic responses from initial treatment in multiple myeloma patients who did not undergo an…
ChemioCare Developing New Lenalidomide Skin Patch
Aiming to improve lenalidomide‘s safety and efficacy, ChemioCare is setting up to develop a new treatment formulation delivered through a skin patch, maintaining an…
MMRF Launches Fund to Invest in Innovative Firms for Multiple Myeloma Research
The Multiple Myeloma Research Foundation (MMRF) has launched the Myeloma Investment Fund in an effort to attract promising biotech and technology companies to the…
Cellectis Plans Clinical Trial to Test Donor-derived CAR T-cell Therapy, Possible Multiple Myeloma Treatment
Cellectis announced plans to open a Phase 1 clinical trial to evaluate UCARTCS1 — its first allogeneic (donor-derived) CAR T-cell therapy for multiple myeloma patients —…
Trial to Evaluate Daratumumab/Revlimid as Maintenance for Some Multiple Myeloma Patients
Janssen Biotech is planning a new Phase 3 clinical trial to explore a combination of under-the-skin daratumumab plus Revlimid (lenalidomide) as a maintenance treatment for…
MolMed Receives Green Light for Phase 1/2 Trial to Test CAR T-cell Therapy in Myeloma, Leukemia Patients
The Italian Medicines Agency has approved a first-in-human clinical trial testing MolMed’s investigational CAR T-cell product, CD44v6, for the treatment of acute myeloid…
